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Abstract 
A large body of both theoretical and empirical literature has affirmed a positive impact of 
human capital accumulation in the form of health on economic growth. Yet Baumol (1967) 
has presented a model in which imbalances in productivity growth between a ‘progressive’ 
(manufacturing) sector and a ‘nonprogressive’ sector of the economy (of which health care 
forms an integral part) lead to perpetual expenditure shifts into the latter and, as a 
consequence, to a decline in overall GDP growth. Which of the two views has an empirical 
grounding is here tested by means of Granger causality analysis of a panel of 21 OECD 
countries. The results do not lend support to the hypothesis that health capital formation 
fosters economic growth in rich countries. They are more in line with the predictions of 
Baumol’s model of unbalanced growth. 
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1. Introduction 
Ever since Solow’s (1957) growth model has been ‘augmented’ by human capital, the growth-
enhancing role of human capital accumulation has been recognized. The pioneering empirical 
studies by Barro (1991) and Mankiw, Romer and Weil (1992) focused on the educational 
dimension of human capital, yet it has been known for long that human capital can also be 
accumulated by improving the health status of the population (Schultz, 1961, Mushkin, 1962). 
Weil’s (2007) paper is the most recent in a chain of studies that have affirmed the growth-
enhancing role of health capital formation empirically.  
On the other hand, Weil (2007: 1295) also suggests that health’s positive effect on GDP is 
strongest among poor countries. For rich countries, the existing empirical evidence on 
whether health capital formation stimulates GDP growth at all is mixed. For instance, while 
Rivera and Currais (1999a, 1999b, 2003) find a positive effect of health expenditure growth 
on productivity growth for OECD countries, Knowles and Owen (1995, 1997) as well as 
McDonald and Roberts (2002) reject the hypothesis that life expectancy is a statistically 
significant explanatory variable for productivity growth in high-income countries. Bhagrava 
et al. (2001) even estimate a negative effect of the adult survival rate on economic growth for 
the US, France, and Switzerland.1 Acemoglu and Johnson (2006) reach a similar conclusion. 
A possible reason why the impact of health capital formation on GDP growth might turn 
negative in the process of economic development is offered by Baumol’s (1967) model of 
‘unbalanced growth’. According to this model, imbalances in productivity growth between a 
‘progressive’ (manufacturing) sector and a ‘nonprogressive’ (services) sector lead to perpetual 
expenditure shifts into the latter. As a consequence of these expenditure shifts, the growth rate 
of overall GDP will decline. Interestingly, Baumol singles out the health sector as a cardinal 
example for an industry beset by which has to become known as the ‘Cost disease’.  
So far, the ‘health and growth’-literature – focusing on the compelling supply-side 
arguments in support of a growth-enhancing role of health capital formation – has largely 
ignored the adverse structural change effect that Baumol (1967) calls attention to. On the 
other hand, the literature on structural change – for which Baumol’s model of unbalanced 
growth is one of its cornerstones – has recently discovered health capital formation as a 
                                                 
1
 Drawing on current life tables, the adult survival rate measures the probability that a 15-year-old will reach the 
age of 60. 
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possible ‘cure’ for ‘Baumol’s (Cost) Disease’.2 My aim in this paper is to bring these two 
strands of literature together and to investigate the causal relationship between health capital 
formation and GDP growth empirically. The empirical part of the paper focuses on rich 
countries because, for one thing, the growth-stimulating effect of health capital formation in 
poor countries is uncontested and, for another thing, ‘Baumol’s Disease’ is a phenomenon 
that affects mainly developed economies. The econometric methodology I will use – the 
(dynamic) panel Granger causality framework – is relatively new and has (to the best of my 
knowledge) not been applied to study the relationship between health capital formation and 
economic growth before.  
The paper is organized as follows. The next section introduces Baumol’s model of 
unbalanced growth and discusses some theoretical and empirical controversies around it. 
Section 3 goes on to survey the state of the (empirical) ‘health and growth’-literature. Section 
4 opens up the empirical part of the paper introducing the data and methods to be used in the 
estimations, especially the methodology of (dynamic) panel Granger causality tests. Section 5 
presents the results of the causality analysis including results of some robustness checks, and 
section 6 concludes.  
 
2. Baumol’s model of ‘unbalanced growth’ revisited 
William J. Baumol’s (1967) article ‘Macroeconomics of unbalanced growth’ is widely 
regarded as a major contribution to the literature on structural change. Whereas the first 
champions of the ‘tertiarization hypothesis’, Allan Fisher (1935) and Colin Clark (1940), 
traced back the gradual shift in production from the agricultural to the manufacturing sector 
and onwards to the services sector mainly to changes in demand, Baumol offers a supply-side 
explanation.3 In a nutshell, his model tells the following story. Productivity growth is higher 
in the ‘progressive’ (secondary) than in the ‘nonprogressive’ (tertiary) sector, but wages grow 
more or less the same in both sectors. Therefore, unit costs and also prices rise much faster in 
the tertiary sector than in the secondary. Demand for certain services, like health care for 
instance, is hardly price-elastic, hence consumers are willing to pay the higher prices. 
Therefore, an ever higher share of total expenditures will be channeled into the services sector 
– hence the ‘Cost disease’. Also, since aggregate productivity growth is a weighted average of 
                                                 
2
 In a purely theoretical paper, Pugno (2006) sets up an endogenous growth model and hypothesizes that the 
growth-stimulating effect of health capital formation is likely to overcompensate the adverse sectoral shift effect 
when it comes to GDP growth. 
3
 For a survey of the different ‘tertiarization’ theories, cf. Schettkat and Yocarini (2006). 
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the sectoral productivity growth rates with the weights provided by the nominal value added 
shares, the aggregate productivity growth rate will decline over time as the sector with the low 
productivity growth receives an ever-increasing weight. Thus, Baumol’s model of unbalanced 
growth predicts a tendency for per-capita output in mature economies to stagnate.  
The model is based on one fundamental assumption, namely that ‘regular’ growth in labor 
productivity can only occur in the ‘progressive’ sector. It is important to understand what the 
term ‘regular’ here means. For Baumol, regular productivity growth is the result of 
technological innovation which manifests itself in new capital goods. Capital goods are also 
responsible for economies of scale, being another source of productivity growth. Regular 
productivity growth is thus defined to depend on certain technological requirements. In the 
service industries, Baumol argues, and also in agriculture and construction, physical capital 
cannot be employed on the same scale as in manufacturing. These industries he therefore 
relegates to the ‘nonprogressive’ sector.4 Baumol does not claim that increases in labor 
productivity are impossible in the ‘nonprogressive’ sector, only that this sector comprises 
“activities which, by their very nature, permit only sporadic increases in productivity” 
(Baumol, 1967: 416). In his model, Baumol abstracts from productivity increases in the 
‘nonprogressive’ sector for simplicity. 
Another simplifying assumption for the model is that labor is the only factor of 
production. Baumol (1967: 417) admits that this assumption is “patently unrealistic”, yet it 
can be seen as a consequence of his basic assumption mentioned before because in the 
simplest version of the model, the ‘nonprogressive’ sector uses no capital. The employment of 
capital in the ‘progressive’ sector Baumol captures – at least over time – by postulating that 
labor productivity in this sector grows at an exogenous rate. 
Next, Baumol assumes that nominal wages in both sectors are related in the long run. He 
simplifies further and assumes that they are equal. His final assumption is that nominal wages 
(in both sectors) rise to the same extent as labor productivity in the ‘progressive’ sector. This 
implies that the price level in the ‘progressive’ sector stays constant, whereas it rises in the 
‘nonprogressive’ sector in order to keep the level of real wages in line with the productivity 
                                                 
4
 In the face of the all-round use of medical technology, the relegation of health care to the ‘nonprogressive’ 
sector may seem odd. Baumol points to the fact, however, that health care differs from manufacturing in that 
capital is here normally not used as a substitute for labor. “The bulk of our municipal expenditures”, he writes, 
“is devoted to education which … offers very limited scope for cumulative increases in productivity. The same is 
true of police, of hospitals, of social services, and of a variety of inspection services. Despite the use of the 
computer in medicine …, there is no substitute for the personal attention of a physician …” (Baumol, 1967: 
423). The issue of productivity growth in the health sector is also discussed in Hartwig (2008b). 
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level. The workers, regardless in which sector they work, buy goods and services from both 
sectors so that their respective real wages converge. 
Equations (1) and (2) formally describe the production functions of the two sectors. Labor 
productivity in the ‘nonprogressive’ sector (1) stays constant, whereas it grows in the 
‘progressive’ sector (2) at the constant rate r. Thus, output in the two sectors (Y1 and Y2) at 
time t is given by: 
1 1t tY aL=                (1) 
2 2
rt
t tY bL e=               (2) 
with L1 and L2 as quantities of labor employed in the two sectors and a and b as constants.  
According to one of the assumptions just mentioned, the nominal wage (in both sectors) is 
given by: 
rt
tW We=                (3) 
with W as an arbitrary starting value. 
Equation (3) completes the model of ‘unbalanced growth’ already. This simple model has a 
couple of interesting implications which Baumol draws out. First, the ‘Cost disease’: 
equations (4) and (5) show that costs per unit of output in the ‘nonprogressive’ sector (C1) 
tend towards infinity while they stay constant in the ‘progressive’ sector (C2). 
1 1 1 1 1/ / /
rt rt
t t t t tC W L Y We L aL We a= = =            (4) 
2 2 2 2 2/ / /
rt rt
t t t t tC W L Y We L bL e W b= = =            (5) 
Relative costs also tend towards infinity (C1 / C2 = bert / a). Under ‘normal’ circumstances – 
that is when prices rise in proportion to costs and when demand is price-elastic – the 
‘nonprogressive’ sector will vanish. Baumol (1967: 421) invokes craftsmanship, fine 
restaurants, and theatres as examples of establishments that have either disappeared or 
retreated to luxury niches as a consequence of customers’ unwillingness to tolerate the price 
increases that would have been necessary to cover rising costs.  
Yet parts of the ‘nonprogressive’ sector produce necessities for which the price elasticity is 
very low. Baumol calls attention to education and health care as prime examples. To show 
what happens in these industries as a consequence of ‘unbalanced growth’, Baumol assumes 
that the relation of real output of the two sectors remains unchanged as in (6): 
 1 2 1 2( / ) / / rtb a Y Y L L e K= = ,            (6) 
with K = const. If L (= L1 + L2) is the labor force, it follows: 
 1 1( ) rtL L L Ke= −  ⇔ 1 /(1 )rt rtL LKe Ke= +          (7) 
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and 2 1 /(1 )rtL L L L Ke= − = +             (8) 
From (7) and (8) we learn that, over the years (t → ∞), L1 tends towards L, and L2 tends 
towards zero.  
Finally, it can be shown what happens to the GDP growth rate under these conditions. Let I 
be an index for real GDP which is calculated as a weighted average of the value added of the 
two sectors: 
 1 1 2 2 1 1 2 2
rtI B Y B Y B aL B bL e= + = +            (9). 
Then, if we insert (7) and (8) into (9) we get: 
 1 2( ) /(1 ) /(1 )rt rt rt rtI L KB a B b e Ke Re Ke= + + = +          (10), 
with 1 2( )R L KB a B b= +              (11). 
Applying the quotient rule leads to: 
 
2 2
2
/ [ (1 ) ] /(1 )
/(1 )
rt rt rt rt
rt rt
dI dt R re Ke Kre Ke
rRe Ke
= + − +
= +
         (12). 
We can calculate the growth rate of real GDP as: 
 ( / ) / /(1 )rtdI dt I r Ke= +             (13). 
It follows that over time (t → ∞) the GDP growth rate drops asymptotically to zero ceteris 
paribus.5  
Since its inception, the model of unbalanced growth has received much attention, both 
from economists working in the theoretical and empirical departments. In a theoretical vein, 
early critics focused on the almost complete neglect of the demand side in the model,6 yet, 
since this is a common feature of growth models in the neoclassical tradition, this line of 
argument was not particularly damaging to Baumol’s model. The supply-side core of the 
model didn’t come under severe attack until Oulton (2001) was able to show that if the 
tertiary sector produces intermediate services instead of services to the final consumer, the 
aggregate productivity (and hence the GDP) growth rate may rise over time rather than fall. 
However, Sasaki (2007) vindicated Baumol’s result of a tendency for the economy to 
stagnate, showing that the GDP growth rate will decline in the long run as long as some 
services are produced for final demand. This result is only subject to the condition that 
productivity growth in the ‘nonprogressive’ sector is indeed smaller than in the ‘progressive’ 
sector, as Baumol assumes.  
                                                 
5
 Ceteris paribus here especially means that L remains constant. If L grows at the rate m, then m must be added 
at the right hand side of (13).  
6
 Cf. Harvey (1998) for a survey of the theoretical debate over Baumol’s model during the first three decades 
after its inception.  
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Whether this assumption is valid has been investigated in a large body of empirical 
studies. Until recently, the empirical evidence was all but unanimously favorable to Baumol’s 
model. Rowthorn and Wells (1987), Rowthorn and Ramaswamy (1997), Scarpetta et al. 
(2000), Wölfl (2003, 2005), and ECB (2006) are just a few examples for comparative multi-
country studies that found productivity growth in manufacturing to be higher than in the 
aggregate of service industries. Fixler and Siegel (1999) confirm this finding in U.S. data. 
However, on the basis of a new dataset for the U.S., Triplett and Bosworth (2003, 2004, 2006) 
have raised doubts whether this ‘stylized fact’ is valid any longer. Taking output data from the 
Bureau of Economic Analysis’ (BEA) industry output and input program and measuring labor 
input with BEA’s series on persons engaged in production (full-time equivalents), Triplett and 
Bosworth (2004, table A−3) compute average annual productivity growth rates of 1.8 percent 
for the ‘goods-producing industries’ and of 2.3 percent for the ‘service-producing industries’ 
over the period 1995−2001. Consequently, they claim that ‘Baumol’s Disease has been cured’ 
(Triplett and Bosworth, 2003, 2006). Still, since neither their ‘goods-producing industries’ 
match Baumol’s ‘progressive sector’ nor their ‘service-producing industries’ match Baumol’s 
‘nonprogressive sector’, Triplett and Bosworth may have been too rash to dismiss ‘Baumol’s 
Disease’, as Hartwig (2006, 2008a) argues. In fact, Bosworth and Triplett (2007) repeat their 
earlier calculations with revised U.S. National Accounts data and find their result of a higher 
productivity growth in the services sector than in the goods sector reversed. 
As was mentioned in the introduction, Pugno (2006) has recently presented a challenge to 
Baumol’s stagnationist outlook for the overall economy that does not rely on the possible 
non-validity of Baumol’s fundamental assumption. Pugno argues that education and health 
care – the two services that Baumol (1967) uses as prime examples for ‘nonprogressive’ 
activities7 – are on the other hand major contributors to the accumulation of human capital. 
Pugno hypothesizes that the growth-stimulating effect of health capital formation could even 
overcompensate the adverse sectoral shift effect when it comes to GDP growth. The next 
section shows that in the face of the existing empirical evidence, Pugno’s optimism might 
seem warranted. 
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 Even Triplett and Bosworth who are convinced that ‘Baumol’s Disease’ has been cured report very low 
productivity growth for health services (+0.9% per year over the period 1995-2001) and even a negative rate 
(−1.0%) for education (cf. Triplett and Bosworth, 2004, p. 350). There are, however, severe measurement 
difficulties with respect to productivity growth in these industries to which, for instance, Nordhaus (2008) calls 
attention. 
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3. Health capital formation and economic growth – a review of the literature 
As was mentioned in the introduction, the notion of health as a component of human capital 
has been introduced in the early 60s already. In the famous Grossman (1972) model, the 
individual’s desire to invest in his or her (depreciating) health capital stock explains the 
demand for health care. The growth literature has in turn identified investment in human 
capital as a driver of economic growth. So, not surprisingly, a number of studies have tried to 
determine the hypothesized contribution of health capital formation to growth empirically. 
The first problem to solve in this literature is to measure health capital formation 
adequately. As can be seen from Table 1, which summarizes characteristics and results of a 
number of relevant studies in this field in chronological order, there are two main 
approaches.8 Sixty percent of the studies rely on some measure of life expectancy or the adult 
survival rate in order to proxy health capital formation; another third choose health care 
expenditures (HCE) as a measure.9 For the present study, I prefer the HCE approach for two 
reasons. First, health economists commonly trace back the lion’s share of the increase in 
global life expectancy to factors such as economic development, better nutrition, and 
improvements in environmental conditions (where they have occurred) rather than to health 
care utilization (cf. Getzen, 1997: 330, Henderson, 1999: 142, Santerre and Neun, 2000: 69, 
Folland, Goodman and Stano, 2001: 118). Therefore, to proxy health capital formation with 
advances in life expectancy would loosen the link between health capital and health care that 
exists, for instance, in the Grossman model. Secondly, of course, by identifying health capital 
formation with health expenditure it is possible to build a bridge to Baumol’s model of 
unbalanced growth, which predicts expenditure shifts towards the ‘nonprogressive’ sector.  
 
< Insert Table 1 around here > 
 
If we focus on the five studies in Table 1 that use measures of health expenditure as a proxy 
for health capital formation, we notice that all of them find a significantly positive impact of 
health capital formation on economic growth.10 The same is true for the rest of the studies – 
with the exception of Webber (2002)11 – when the full sample of countries is considered, 
although, as has been mentioned in the introduction, results (not shown in Table 1) are 
                                                 
8
 For similar compilations, cf. Tompa (2002) and Bloom, Canning and Sevilla (2004). 
9
 Plus there is one study that uses calorie intake. 
10
 The coefficients in Table 1 are not directly comparable since the models and samples differ. 
11
 Weil (2007) doesn’t use regression analysis to arrive at the estimate reported in Table 1. 
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sometimes different for the group of developed economies. Nevertheless, concerning the 
matter of dispute this paper sets out to resolve – whether health care expenditure growth 
through its impact on human capital formation fosters economic growth or, conversely, 
whether it leads to stagnation because it is the result of a ‘Cost disease’ that adversely affects 
the structure of the economy – the existing empirical evidence seems to support the former 
view.  
However, if we take a closer look at the five studies mentioned, it appears that they do not 
yet provide enough evidence to close the case. All these studies use an augmented Solow 
growth modeling framework, which, in a cross-sectional design, does not allow for causal 
inferences. The positive contemporaneous association of GDP and HCE growth may be the 
result of ‘reverse causation’, as it is well known from the broad literature on the determinants 
of health care expenditure growth (recently summarized in Hartwig, 2008b) that GDP – or 
national income, respectively – is a very robust explanatory variable for health care 
expenditure.12 Admittedly, Heshmati (2001) and Rivera and Currais in their various 
publications test for endogeneity using the Hausman (1978) test, yet no clear picture emerges. 
While Heshmati (2001) and Rivera and Currais (2004) cannot reject the hypothesis of 
exogeneity for health care expenditure, Rivera and Currais (1999a, 1999b, 2003) do find 
evidence for endogeneity and account for that by using instrumental variables in their 
estimations. It is unclear, however, whether the variables they propose as instruments are 
indeed appropriate since – as was just mentioned – the literature offers very little guidance as 
to the determinants of HCE growth (other than GDP growth). Also, Rivera and Currais’ 
instrumental variables (IV) estimations are based on a cross-section of 24 OECD countries 
hence the number of observations is very limited.13 At any rate, there still seems to be room 
for further research into the nexus between health care expenditure and economic growth. The 
present study aims at providing new evidence on the causal links between these two variables. 
In comparison to the earlier studies, more observations and a different methodology will be 
used. The next section will introduce the data as well as this different methodology, which is 
the (dynamic) panel Granger causality testing approach. 
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 Hoffmeyer and McCarthy (1994: 67) and Roberts (1999: 459) even suggest that GDP is the only robust 
determinant of health care expenditure that health economists have been able to uncover. 
13
 Heshmati’s (2001) data cover the period 1970-1992. He calculates four five-year averages and one three-year 
average, and he has 22 OECD countries in his panel. His database thus consists of 110 observations. Rivera and 
Currais (2004) also use a panel approach with five five-year averages over the period 1973-1993. For the 17 
Spanish regions they look at, this yields 85 observations. 
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4. Methodology and data 
Baumol’s model of unbalanced growth predicts that structural change will cause the GDP 
growth rate to decline over time. Periods of strong increases in health care expenditure (HCE) 
are seen as episodes in which both employment and expenditures shift to a sector – or, insofar 
as HCE growth is symptomatic for an all-round ‘Cost disease’ – to sectors with low 
productivity growth. Later periods should then be characterized by lower GDP growth.  
Otherwise, if Pugno (2006) was right, health expenditure forms human capital which, with 
a time-lag, should increase economic growth. In order to test which of these two hypotheses 
has an empirical grounding, we need a methodology that keeps track of the time-lags involved 
and that ascertains that causes, if we can identify them, precede effects. Both these aspects 
suggest choosing the methodology of Granger causality testing for the empirical part of this 
paper.  
Granger’s (1969) definition of causality has in the meantime become a standard analytical 
tool in applied econometrics. According to this definition, a stationary time series Yt is said to 
‘cause’ another stationary time series Xt if – under the assumption that all other information is 
irrelevant – the inclusion of past values of Yt significantly reduces the predictive error 
variance of Xt. In econometric practice, whether Yt Granger-causes Xt is typically tested by 
regressing Xt on its own lags and on lags of Yt. If the lags of Yt are found to be jointly 
statistically significant, then the hypothesis that Yt Granger-causes Xt cannot be rejected. 
(Granger causality running from Xt to Yt can be tested in the same way.) 
More recently, the notion of Granger causality has found its way into panel econometrics. 
Most of the papers that have employed a panel Granger causality framework since around the 
beginning of the new millennium have investigated the causal nexus between certain variables 
and economic growth. For instance, there are papers that focus on ‘investment and growth’ 
(Attanasio, Picci and Scorcu, 2000, Podrecca and Carmeci, 2001) or, more narrowly, on 
‘foreign direct investment and growth’ (Nair-Reichert and Weinhold, 2001, Laaksonen-Craig, 
2004, Hsiao and Hsiao, 2006). The panel Granger causality approach has also been used to 
study the relationship between exports and growth (Chao and Buongiorno, 2002, Kόnya, 
2006), agriculture and growth (Tiffin and Irz, 2006), social security and growth (Lee and 
Chang, 2006) and financial development and growth (Hurlin and Venet, 2004, Miyakoshi and 
Tsukuda, 2004, Al-Awad and Harb, 2005). As far as I see, the present paper is the first to 
apply the panel Granger causality methodology to the field of ‘health and growth’. 
Since the methodology of panel Granger causality testing is not implemented identically 
in the literature just reviewed – for instance, not all papers impose the restriction that the 
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coefficients of the lagged Xt and Yt variables are the same for all cross-section members – a 
few more words are necessary about how the method will be implemented here. First, as is 
quite standard in the literature just reviewed as well as in the broader literature on economic 
growth, the HCE and GDP level data will be transformed into five-year average annual 
growth rates (geometrical means) in order to eliminate the cyclical component. As the 
Granger causality tests require the data to be stationary, the resulting time series will be tested 
for the presence of unit roots, applying a battery of now standard panel unit root tests. When 
these tests fail to detect unit roots, the panel estimation models can be set up, for which the 
restriction of identical coefficients of the lagged Xit and Yit variables will be imposed. Thus, I 
will estimate a time-stationary VAR model adapted to a panel context (as in Holtz-Eakin, 
Newey and Rosen, 1988) of the form: 
0
1 1
m m
it l it l l it l i it
l l
X X Y uα α δ µ
− −
= =
= + + + +∑ ∑      (14).  
Xit and Yit are the five-year averages of the growth rates of per-capita GDP and HCE, 
respectively. N countries (indexed by i) are observed over T periods (indexed by t). I allow 
for country-specific effects µi. The disturbances uit are assumed to be independently 
distributed across countries with a zero mean. They may display heteroscedasticity across 
time and countries, though. 
It is common in Granger causality studies to test whether causation runs in both 
directions. So although the main focus of this paper is on testing whether HCE growth 
Granger-causes GDP growth – and if so, with which sign – I will also estimate the equation: 
0
1 1
m m
it l it l l it l i it
l l
Y X Y vβ β γ η
− −
= =
= + + + +∑ ∑                (15).14  
It will be interesting to see whether the panel Granger causality methodology confirms health 
economists’ ‘stylized fact’ that GDP is a significant explanatory variable for health care 
expenditure.15  
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 The assumptions are the same as for equation (14). 
15
 As far as I see, the only two studies in this field of research that have used the Granger causality approach so 
far are the papers by Devlin and Hansen (2001) and Erdil and Yetkiner (2008). Devlin and Hansen find Granger 
causality running from GDP to HCE for 8 OECD countries out of 20 (only) in a sample of annual data that 
covers the period 1960−1987. Granger-causality running from HCE to GDP is also found for 8 countries. Erdil 
and Yetkiner’s (annual) data cover a sample of 75 high to low income countries over the 90s. Their study finds 
bi-directional Granger-causality for 46 countries, Granger-causality running only from GDP to HCE for 12 
countries and Granger-causality running only from HCE to GDP for 10 countries. Neither Devlin and Hansen 
nor Erdil and Yetkiner report the signs of their estimated coefficients. 
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Estimating equations (14) and (15) with pooled OLS presents an endogeneity problem 
since if the dummy variables (country-specific effects) affect GDP growth in (14) and HCE 
growth in (15) in one period, they presumably affected them in the previous period also (cf. 
Nickell, 1981). The first step into the direction of correcting this endogeneity problem in 
dynamic panels is to take the first difference of all variables and to thereby eliminate the 
individual effects. Still, there remains a correlation between the lagged dependent variable, 
which is now in differences, and the error term. Arellano and Bond (1991) have shown that 
the best way around this problem is to use lags of the dependent variable from at least two 
periods earlier (in levels) as well as lags of the right-hand side variables as instruments in a 
Generalized Method of Moments (GMM) estimator. Arellano and Bover (1995) and Blundell 
and Bond (1998) suggest to difference the instruments instead of the regressors in order to 
make them exogenous to the fixed effects. This leads from the ‘difference’ GMM to the 
‘system’ GMM estimator (cf. Roodman, 2006). In the next section, I will present results using 
the OLS, Arellano-Bond one-step system GMM, and Arellano-Bond two-step system GMM 
estimators. For the latter, the finite sample correction recently proposed by Windmeijer 
(2005) will be applied.  
Based on the estimation results, a conclusion on causality will be reached by running 
Wald tests on the coefficients of the lagged Yt’s to check whether they are jointly statistically 
different from zero.16 
Data on health care expenditure are taken from the OECD Health database (in the version 
of October, 26, 2007). This database also contains demographic and economic entries so that 
all data needed for the purpose of the present paper can be gathered from this source. 
Data on per-capita health care expenditure with a frequency of at least five years and a 
starting point around 1970 are available for 21 countries from the OECD Health database. 
These 21 countries are Australia, Austria, Belgium, Canada, Denmark, Finland, France, 
Germany, Iceland, Ireland, Japan, Luxembourg, Netherlands, New Zealand, Norway, 
Portugal, Spain, Sweden, Switzerland, the United Kingdom, and the United States.17 All series 
end in 2005. From these data it is therefore possible to construct a balanced panel with 21 
cross-sections and a time dimension of seven five-year-average growth rates. The panel thus 
consists of 147 observations (which is a clear improvement over the earlier empirical ‘health 
and growth’ literature that was discussed in section 3).  
                                                 
16
 Podrecca and Carmeci (2001) follow a similar approach to estimation and causality testing.  
17
 The Danish series starts in 1971, the Dutch in 1972. 
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 Data on real per-capita GDP (growth) are available for the same group of countries and 
period of time. In addition, I need data for the GDP deflator (which are also available from 
the OECD Health database) in order to deflate HCE – prior to calculating per-capita values 
and averaging growth rates, of course. Deflating nominal HCE with the GDP deflator is 
necessary to eliminate the upward trend in HCE that is due to purely monetary factors, or 
general inflation, respectively. If Baumol (1967) was right, then nominal HCE should grow 
more than nominal GDP – or HCE deflated by the GDP deflator should grow faster than real 
GDP – leading to a rise in the share of HCE in nominal GDP. This is precisely the ‘Cost 
disease’ point of view.18 The next section will go on to present the results of the causality 
analysis, including results of some robustness checks. 
 
5. Empirical results 
A reasonable first step in empirical analysis is a visual inspection of the data. Figures 1 and 2 
show the histograms of the per-capita GDP and per-capita HCE growth rates – both deflated 
by the GDP deflator – for my sample of 21 OECD countries. Obviously, health care 
expenditure has outgrown GDP. The median growth rate of real per-capita HCE is 3.6 
percent, whereas the median growth rate of real per-capita GDP is only 2.2 percent.  
 
< Insert Figures 1 and 2 around here > 
 
Both per-capita GDP and HCE growth exhibit one large positive outlier. Ireland’s per-capita 
GDP has grown by an amazing 8 ½ percent per year on average over the period 1995-2000. 
Even more extreme is Portugal’s health expenditure growth between 1970 and 1975, a period 
in which real per-capita HCE more than doubled in this country. Outliers like these suggest 
that, as a robustness check, equations (14) and (15) should not only be estimated for the full 
sample of countries, but also by dropping each of the 21 countries in turn. Results of this 
robustness test will be presented below. 
In order to test for Granger causality between GDP and health care expenditure, it is 
necessary that the two time series are stationary. Unfortunately, the available panel unit root 
tests are mainly designed for panels where both the time dimension and the cross section 
                                                 
18
 Health economists have indeed identified an ‘excess health care price/cost inflation’ (Huber, 1999), albeit 
without tracing it back to Baumol’s model of unbalanced growth. This has only recently been done by Hartwig 
(2008b). 
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dimension are relatively large.19 In panels such as mine with a time dimension of only 7 
observations, the analysis can proceed only under restrictive assumptions like, for instance, 
dynamic homogeneity. This has to be kept in mind when interpreting the results of panel unit 
root tests reported in Table 2.20 As the table shows, the tests reject the null hypothesis of non-
stationarity for both variables. For what they are worth, these test results at least do not speak 
against proceeding to the Granger causality tests.  
Since Granger causality test results are sensitive to the choice of lag length m in the time-
stationary VAR model given by equation (14), it is important to specify the lag structure 
appropriately. I follow Miyakoshi and Tsukuda (2004) in estimating equation (14) with OLS 
and basing the choice of the optimal lag length on the Schwarz Information Criterion (SIC). 
Table 3 shows that – based on this criterion – the optimal lag length is two.  
 
< Insert Table 3 around here > 
 
Table 4 shows the results for estimating the VAR model (14) with OLS, with the Arellano-
Bond one-step system GMM estimator and with the Arellano-Bond two-step system GMM 
estimator, respectively.21 The OLS specification includes country-specific fixed effects 
(random effects were rejected by the Hausman test for correlated random effects.) The GMM 
specifications include period-specific effects. Lags of the dependent variable from at least two 
periods earlier as well as lags of the per-capita HCE growth variables serve as GMM-style 
instruments.22 For the two-step estimator, the small sample correction proposed by 
Windmeijer (2005) has been implemented.  
 
< Insert Table 4 around here > 
 
The bottom of the table reports specification test results for the GMM estimations. The 
Sargan test is a test on whether the instruments are uncorrelated with the error term uit (which 
they must be in order to be valid instruments). Table 4 shows that the null hypothesis is 
                                                 
19
 For a detailed account of panel unit root tests, cf. Breitung and Pesaran (2008). 
20
 The table reports results for the panel unit root tests available in EViews. The estimations for this paper were 
done either with EViews (v. 6) or with Stata (v. 9).  
21
 The Arellano-Bond one-step estimator uses the identity matrix as a weighting matrix. The two-step estimator 
weighs the instruments asymptotically efficient using one-step estimates. 
22
 Roodman’s ‘xtabond2’ command was used in Stata (v. 9) for the GMM estimations; and Roodman’s (2006) 
examples geared my handling of the syntax.   
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accepted.23 Note, however, that it is necessary to ‘collapse’ the set of instruments in order to 
achieve that the Sargan test accepts the over-identifying restrictions in the GMM estimations. 
While in the standard instrument matrix each instrumenting variable generates one column for 
each time period and lag available to that time period, Roodman (2006) proposes to ‘collapse’ 
the instrument set into a single column to limit the instrument count. This option is available 
in Stata (v. 9) and has been used here. The Arellano-Bond test accepts the hypothesis of no 
second-order autocorrelation in the disturbances of the first differenced equation. 
The estimations consistently find negative coefficients for lagged per-capita health care 
expenditure. The second lag is always statistically significant. In the (OLS and) Arellano-
Bond one-step estimation(s), the Wald test rejects the hypothesis that the coefficients of 
lagged per-capita HCE are jointly equal to zero. If they aren’t, then growth in real per-capita 
health care expenditure Granger-causes real GDP growth with a negative impact.  
There are at least two ways of interpreting this result. First, it could be seen as providing 
evidence against the model of endogenous growth that Pugno (2006) defends. In the standard 
neoclassical (exogenous) growth model, negative coefficients for the human capital variable 
are perfectly plausible within a Granger-causality framework. Starting from a steady state, a 
positive shock to health capital formation should boost GDP growth in the same time period. 
Later periods should then be characterized by lower growth as the growth rate falls back to its 
steady state level. Of course, while in the standard Solow model technological progress 
ensures that the steady state growth rate can remain positive, Baumol shows that when we 
assume ‘unbalanced growth’ in a two-sectoral model, the per-capita GDP growth rate will 
drop to zero despite technological progress (in the ‘progressive’ sector). 
If we choose to stick to the endogenous growth model, however, then the finding of 
negative Granger-causality running from per-capita HCE to per-capita GDP growth 
undermines Pugno’s (2006) conjecture that health capital formation might have cured the 
‘Cost disease’ through its growth-stimulating effect (which overcompensates the adverse 
sectoral shift effect). This statement carries over to the Arellano-Bond two-step estimation 
which, although it does not find negative Granger-causality running from HCE to GDP 
growth at conventional significance levels, does not find any positive Granger-causality that 
would support Pugno’s claim. Based on the evidence Table 4 reports, the research question 
                                                 
23
 The Sargan statistic, which is the minimized value of the one-step GMM criterion function, is not robust to 
heteroskedasticity or autocorrelation. The Hansen statistic (which is the minimized value of the two-step GMM 
criterion function) is robust. 
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that motivated this paper, namely whether health capital formation has cured ‘Baumol’s 
Disease’, has to be answered in the negative. 
Skeptics might object to the methodology employed to derive this result that it rests on the 
assumption that all information not included in the stationary VAR model is irrelevant. 
However, this assumption could be defended here on the grounds that the list of robust 
determinants of economic growth is not very long. Sturm and de Haan (2005), for instance, 
find only real capital formation and a couple of regional dummies (that are not relevant for 
my sample of OECD countries) to be significant and robust explanatory variables for GDP 
growth. To account for their findings, I added lagged per-capita growth in fixed investment to 
model (14) as a control variable. This didn’t change the coefficients and Wald test results for 
HCE growth qualitatively. 
Yet, there is still the possibility that the results Table 4 presents are driven by outliers. To 
check the robustness of these results, I therefore re-estimate equation (14) dropping each of 
the 21 countries in turn. Table 5 shows that the results are indeed to some extent sensitive to 
the exclusion of Portugal and Ireland. The Wald test nevertheless rejects the hypothesis that 
the coefficients of lagged per-capita HCE are jointly equal to zero at the 5 percent level. 
 
< Insert Table 5 around here > 
 
To conclude the empirical analysis, I test for Granger-causality running from GDP to HCE. 
As has been mentioned before, GDP – or national income, respectively – has been identified 
as the most important and robust explanatory variable for health care expenditure by health 
economists. Table 6 shows the results for estimating the VAR model (15).24 As in the 
previous estimations, the GMM specifications include period-specific effects; and lags of the 
dependent variable from at least two periods earlier as well as lags of the per-capita GDP 
growth variables serve as GMM-style instruments. Again, the set of instruments was 
‘collapsed’. Still, the Sargan test does not accept the over-identifying restrictions at the 5 
percent level. The Hansen test, however, does. The Arellano-Bond test clearly accepts the null 
of no second-order autocorrelation in the differenced residuals. 
As can be seen from Table 6, the coefficients of lagged per-capita GDP are always 
positive and significant. The Wald test rejects the hypothesis that they are jointly equal to zero 
at conventional significance levels. Hence we can conclude that per-capita GDP growth 
Granger-causes per-capita HCE growth with a positive sign. This finding – which is robust to 
                                                 
24
 The Schwarz Information Criterion again suggests lag length two. 
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the exclusion of countries from the sample (cf. Table 7) – supports the existing literature on 
the determinants of health care expenditure growth. 
 
< Insert Tables 6 and 7 around here > 
 
6. Conclusion 
The research question this paper poses – whether health capital formation has cured 
‘Baumol’s (Cost) Disease’ – can clearly be answered in the negative. No evidence was found 
that health capital formation through health care expenditure – that is the mechanism 
highlighted by the famous Grossman (1972) model – Granger-causes per-capita GDP growth 
with a positive sign in OECD countries. On the contrary, when per-capita GDP growth is 
regressed on its own lags and on the lags of per-capita health care expenditure in a panel 
Granger-causality testing framework, the coefficients for the lagged HCE growth are 
consistently negative. The statistical significance of the negative coefficients is not robust to 
the choice of the estimator (Arellano-Bond two-step vs. Arellano- Bond one-step system 
GMM), however. 
When the other direction of Granger-causality – that is Granger-causality running from 
per-capita GDP growth to per-capita HCE growth – is tested, the results support health 
economists’ long-standing ‘stylized fact’ that GDP determines HCE with a positive sign. My 
findings thus support the idea of some kind of self-stabilizing control cycle between GDP and 
health care expenditure. According to this idea, the strong HCE growth that occurred during 
the 50s and 60s in many OECD countries subsequently led to a decline in GDP growth 
because of the adverse structural change effect highlighted by Baumol’s model. Declining 
GDP growth in turn attenuated HCE growth, and, as a consequence, GDP growth could 
rebound. This mechanism might help to understand why HCE growth in OECD countries 
declined temporarily in the 80s − a fact that Barros’ (1998) model was unable to explain.  
So how are my results related to the conventional wisdom that health is generally a good 
thing for economic growth?25 First, it has to be remembered that my sample of countries 
consists of OECD countries only. Earlier studies (mentioned in the introduction to this paper) 
have occasionally also been unable to determine any positive influence of health on economic 
growth in rich countries. This does not mean that my results necessarily carry over to poor 
countries for which ‘Baumol’s Disease’ will not become acute for a long time yet. Secondly, 
                                                 
25
 Weil (2007: 1266) quotes the World Health Organization’s Commission on Macroeconomics and Health 
which sees ‘powerful linkages’ between health and long-term economic growth.  
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most studies that found a positive impact of health on economic growth used the aggregate 
production function approach and proxied health capital with some measure of the 
population’s health status such as life expectancy at birth. Yet the health status can be 
improved in many ways; and indeed other determinants such as nutrition are generally 
regarded as more important for increasing life expectancy than health care utilization. My 
results point to a negative Granger-causality between health capital formation through health 
care expenditure and GDP growth. They do not preclude that increases in life expectancy 
through, say, better nutrition would stimulate economic growth.  
Still, my results do present a challenge for the way the empirical growth literature 
generally proceeds, that is, by estimating an aggregate production function. If the output level 
is modeled to be a function of certain levels of input (such as health) then it is not surprising 
that increasing the input levels will raise output. Effects such as those highlighted by 
Baumol’s model of unbalanced growth, namely that the process of raising certain input levels 
(such as health and education) can imply structural change that is unfavorable for overall 
economic growth might vanish in the estimates of total factor productivity growth.26 For 
example, it might be the case that the health variable (life expectancy) has a positive sign in 
an estimated production function, but that a positive shock to health expenditure – even if it 
improves life expectancy – lowers total factor productivity to an extent that overcompensates 
the effect of the rise in health status on growth. Nevertheless, the positive sign of the health 
variable may mislead policymakers. To preclude this possibility, future research should find 
ways to cross-validate the conclusions of cross-country growth studies based on the aggregate 
production function approach. 
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Table 1: Macroeconomic growth studies with a focus on health 
Study Growth measure Health measure Countries 
and time 
period 
Coefficient 
Barro and Sala-i-
Martin (1995) 
Growth rate of per-capita 
GDP 
Log of life 
expectancy at birth 
87-97 
countries 
1965-85 
0.064* 
 
Knowles and 
Owen (1995) 
Log difference of GDP 
per employed person 
between 1985 and 1960 
Log of (80 years 
minus life 
expectancy at birth) 
84 countries 
1960-85 
0.381* 
Knowles and 
Owen (1997) 
Log difference of GDP 
per employed person 
between 1985 and 1960 
Log of (80 years 
minus life 
expectancy at birth) 
77 countries 
1960-85 
0.582* – 
0.797* 
Rivera and Currais 
(1999a) 
Log difference of GDP 
per employed person 
between 1990 und 1960 
Log of the share of 
health expenditure 
in GDP 
OECD- 
countries 
1960-90 
0.22* – 0.33* 
Rivera and Currais 
(1999b) 
Log difference of GDP 
per employed person 
between 1990 und 1960 
Log of the share of 
health expenditure 
in GDP 
OECD- 
countries 
1960-90 
0.21* – 0.22* 
Bloom, Canning 
and Sevilla (2001) 
Growth rate of per-capita 
GDP 
Log of life 
expectancy at birth 
104 countries 
1960-90 
0.04* 
Bhargava et al. 
(2001) 
Growth rate of per-capita 
GDP 
Log of the adult 
survival rate 
73-92 
countries 
1965-90 
0.181* – 
0.358* 
Heshmati (2001) Log difference of GDP 
per employed person  
between 1990 und 1970 
Log of per-capita 
health expenditure 
OECD- 
countries 
1970-92 
0.175* 
Webber (2002) Growth rate of GDP per 
employed person  
Calorie intake per 
capita  
46 countries 
1960-1990 
0.08 – 0.22 
McDonald and 
Roberts (2002) 
Log of GDP per 
employed person 
Log of (80 years 
minus life 
expectancy at birth) 
77 countries 
1960-89 
0.12* 
Rivera and Currais 
(2003) 
Log difference of GDP 
per employed person 
between 2000 und 1960 
Log of the share of 
health expenditure 
in GDP 
OECD- 
countries 
1960-2000 
0.18* – 0.26* 
Rivera and Currais 
(2004) 
Growth rate of GDP per 
employed person 
Public health 
expenditure 
17 Spanish 
regions 
1973-93 
0.13* 
Bloom, Canning 
and Sevilla (2004) 
Growth rate of per-capita 
GDP 
Log of life 
expectancy at birth 
104 countries 
1960-90 
0.04* 
Jamison, Lau and 
Wang (2005) 
Log of per- capita GDP Log of the adult 
survival rate 
53 countries 
1965-90 
0.50* 
Weil (2007) (Proportional reduction in 
variance of) log of GDP 
per capita 
Adult survival rate 
(among others) 
92 countries 
NA 
0.099 
* statistically significant at the 5% level 
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Figure 1: Histogram of real per-capita GDP growth 
rates of 21 OECD countries (five-year averages, 1970-
2005) 
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Figure 2: Histogram of real per-capita HCE growth 
rates of 21 OECD countries (five-year averages, 1970-
2005) 
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Table 2: Panel unit root test results (21 OECD countries, 1970-2005) 
 GDPRPC HCERPC 
H0: Unit root in level Stat. Prob. Obs. Stat. Prob. Obs. 
Levin, Lin & Chu t* –13.200 0.000 126 –17.128 0.000 126 
Im, Pesaran & Shin W-stat –5.007 0.000 126 –5.717 0.000 126 
ADF – Fisher  Chi-square 110.494 0.000 126 115.991 0.000 126 
PP – Fisher Chi-square 129.068 0.000 126 168.481 0.000 126 
GDPRPC = real per-capita GDP growth rates (five-year averages), HCERPC = real per-capita health care 
expenditure growth rates (five-year averages) 
Note: Individual intercepts are included as exogenous variables in the test equations. For the first three tests 
listed in the table, maximum lags are automatically selected based on the Schwarz Information Criterion. The 
remaining test uses the Bartlett kernel for the Newey-West bandwidth selection. The probabilities for the Fisher 
tests are computed using an asymptotic Chi-square distribution. All other tests assume asymptotic normality. 
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Table 3: Optimal lag length for equation (14) 
Lag 1 2 3 
SIC 4.088 4.078 4.192 
SIC = Schwarz Information Criterion 
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Table 4: Estimation results for equation (14) 
GDPRPC 
 (1) (2) (3) 
 OLS Arellano-Bond 
one-step GMM 
Arellano-Bond 
two-step GMM 
GDPRPC(−1) −0.327*** 
        (0.113) 
0.346*** 
        (0.125) 
0.283** 
        (0.111) 
GDPRPC(−2) 0.241** 
        (0.116) 
0.484*** 
        (0.139) 
0.477 
        (0.317) 
HCERPC(−1) −0.074 
         (0.075) 
−0.210** 
 (0.083) 
−0.124 
  (0.112) 
HCERPC(−2) −0.107** 
        (0.047) 
−0.179*** 
(0.057) 
−0.140* 
 (0.068) 
Number of obs. 105 105 105 
Wald test (p-level) 0.061 0.002 0.149 
Sargan test (p-level) 
− 
0.524 0.524 
Hansen test (p-level) 
− − 
0.458 
AB test (p-level) 
− 
0.710 0.951 
GDPRPC = real per-capita GDP growth rates (five-year averages), HCERPC = real per-capita health care 
expenditure growth rates (five-year averages) 
Standard errors are in parenthesis. *, ** and *** denote significance at the 10, 5 and 1 percent level, 
respectively. Estimates for constant terms not shown. AB test = Arellano-Bond test for AR(2) in first 
differences. 
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Table 5: Robustness test – Cross-national stability of parameters of model (14): excluded countries 
GDPRPC 
 Australia Austria Belgium Canada Denmark Finland France Germany Iceland Ireland Japan 
GDPRPC(−1) 0.350*** 
    (0.122) 
0.372*** 
    (0.131) 
0.347*** 
    (0.128) 
0.351*** 
  (0.130) 
0.325*** 
(0.121) 
0.358*** 
  (0.125) 
0.345*** 
  (0.128) 
0.335*** 
 (0.129) 
0.316** 
  (0.124) 
0.070 
  (0.133) 
0.397*** 
  (0.124) 
GDPRPC(-2) 0.472*** 
    (0.139) 
0.520*** 
   (0.147) 
0.487*** 
     (0.142) 
0.504*** 
  (0.145) 
0.434*** 
(0.136) 
0.490*** 
  (0.140) 
0.487*** 
  (0.142) 
0.498*** 
(0.143) 
0.509*** 
  (0.144) 
0.242* 
  (0.127) 
0.584*** 
  (0.134) 
HCERPC(-1) 
−0.201** 
     (0.083) 
−0.249*** 
    (0.094) 
−0.208** 
     (0.084) 
−0.207** 
  (0.088) 
−0.179** 
  (0.080) 
−0.181** 
  (0.087) 
−0.215** 
  (0.087) 
−0.232*** 
    (0.084) 
−0.189** 
  (0.084) 
−0.165** 
  (0.078) 
−0.235*** 
   (0.084) 
HCERPC(-2) 
−0.191*** 
    (0.057) 
−0.185*** 
   (0.060) 
−0.179*** 
    (0.058) 
−0.199*** 
    (0.061) 
−0.162*** 
  (0.056) 
−0.168*** 
   (0.058) 
−0.186*** 
   (0.058) 
−0.185*** 
   (0.057) 
−0.152*** 
   (0.056) 
−0.134** 
  (0.052) 
−0.211*** 
   (0.056) 
Number of obs. 100 100 100 100 100 100 100 100 100 100 100 
Wald test 
(p-level) 
0.001 0.002 0.003 0.002 0.005 0.007 0.002 0.001 0.008 0.017 0.000 
 Luxembourg Netherlands New Zealand Norway Portugal Spain Sweden Switzerland U.K. U.S. 
GDPRPC(−1) 0.309** 
(0.132) 
0.343*** 
 (0.127) 
0.355*** 
(0.124) 
0.403*** 
(0.122) 
0.355*** 
(0.129) 
0.345*** 
(0.127) 
0.355*** 
(0.129) 
0.326*** 
 (0.122) 
0.348*** 
 (0.128) 
0.353*** 
(0.128) 
GDPRPC(-2) 0.516*** 
(0.149) 
0.505*** 
(0.141) 
0.294** 
(0.137) 
0.500*** 
(0.137) 
0.439*** 
(0.147) 
0.535*** 
(0.144) 
0.497*** 
(0.143) 
0.471*** 
(0.137) 
0.487*** 
(0.142) 
0.491*** 
(0.143) 
HCERPC(-1) 
−0.206** 
     (0.083) 
−0.237*** 
    (0.084) 
−0.211** 
     (0.087) 
−0.245*** 
   (0.082) 
−0.157* 
   (0.080) 
−0.216** 
  (0.085) 
−0.224*** 
   (0.086) 
−0.204** 
    (0.083) 
−0.207** 
   (0.085) 
−0.218** 
  (0.087) 
HCERPC(-2) 
−0.195*** 
     (0.055) 
−0.204*** 
   (0.058) 
−0.188*** 
     (0.057) 
−0.166*** 
   (0.056) 
−0.136** 
   (0.066) 
−0.182*** 
  (0.057) 
−0.175*** 
   (0.058) 
−0.176*** 
    (0.057) 
−0.178*** 
   (0.058) 
−0.181*** 
   (0.060) 
Number of obs. 100 100 100 100 100 100 100 100 100 100 
Wald test 
(p-level) 
0.001 0.000 0.002 0.001 0.045 0.002 0.002 0.003 0.003 0.003 
GDPRPC = real per-capita GDP growth rates (five-year averages), HCERPC = real per-capita health care expenditure growth rates (five-year averages) 
The Arellano-Bond one-step GMM estimator was applied. Standard errors are in parenthesis. *, ** and *** denote significance at the 10, 5 and 1 percent level, respectively. 
Estimates for constant terms not shown. 
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Table 6: Estimation results for equation (15) 
HCERPC 
 (1) (2) (3) 
 OLS Arellano-Bond 
one-step GMM 
Arellano-Bond 
two-step GMM 
HCERPC(−1) −0.244** 
        (0.099) 
−0.189* 
        (0.102) 
−0.139 
         (0.106) 
HCERPC(−2) −0.382*** 
        (0.062) 
−0.336*** 
        (0.069) 
−0.326** 
        (0.118) 
GDPRPC(−1) 0.438*** 
        (0.149) 
0.493*** 
        (0.153) 
0.568*** 
        (0.163) 
GDPRPC(−2) 0.332** 
        (0.153) 
0.116 
        (0.171) 
0.190 
        (0.168) 
Number of obs. 105 105 105 
Wald test (p-level) 0.010 0.004 0.006 
Sargan test (p-level) 
− 
0.035 0.035 
Hansen test (p-level) 
− − 
0.183 
AB test (p-level) 
− 
0.801 0.781 
GDPRPC = real per-capita GDP growth rates (five-year averages), HCERPC = real per-capita health care 
expenditure growth rates (five-year averages) 
Standard errors are in parenthesis. *, ** and *** denote significance at the 10, 5 and 1 percent level, 
respectively. Estimates for constant terms not shown. AB test = Arellano-Bond test for AR(2) in first 
differences. 
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Table 7: Robustness test – Cross-national stability of parameters of model (15): excluded countries 
HCERPC 
 Australia Austria Belgium Canada Denmark Finland France Germany Iceland Ireland Japan 
HCERPC(-1) 
−0.177* 
    (0.102) 
−0.202* 
    (0.108) 
−0.201** 
     (0.103) 
−0.185* 
   (0.108) 
−0.188* 
 (0.101) 
−0.184* 
   (0.106) 
−0.190* 
   (0.103) 
−0.179* 
 (0.104) 
−0.175* 
   (0.099) 
−0.239** 
   (0.108) 
−0.189* 
   (0.106) 
HCERPC(-2) 
−0.352*** 
    (0.070) 
−0.278*** 
    (0.069) 
−0.357*** 
     (0.071) 
−0.327*** 
   (0.076) 
−0.346*** 
(0.071) 
−0.301*** 
    (0.070) 
−0.344*** 
   (0.070) 
−0.335*** 
(0.071) 
−0.340*** 
   (0.067) 
−0.318*** 
   (0.073) 
−0.338*** 
   (0.071) 
GDPRPC(−1) 0.502*** 
    (0.152) 
0.532*** 
   (0.151) 
0.501*** 
    (0.156) 
0.492*** 
   (0.160) 
0.539*** 
  (0.154) 
0.528*** 
  (0.152) 
0.501*** 
   (0.155) 
0.465*** 
    (0.160) 
0.528*** 
   (0.147) 
0.478*** 
  (0.185) 
0.489*** 
   (0.157) 
GDPRPC(-2) 0.134 
    (0.172) 
0.125 
    (0.168) 
0.129 
     (0.173) 
0.105 
   (0.178) 
0.123 
   (0.172) 
0.122 
   (0.170) 
0.134 
   (0.172) 
0.113 
    (0.178) 
0.087 
   (0.170) 
0.143 
   (0.176) 
0.146 
   (0.169) 
Number of obs. 100 100 100 100 100 100 100 100 100 100 100 
Wald test 
(p-level) 
0.003 0.001 0.004 0.005 0.002 0.002 0.004 0.011 0.001 0.026 0.007 
 Luxembourg Netherlands New Zealand Norway Portugal Spain Sweden Switzerland U.K. U.S. 
HCERPC(-1) 
−0.166* 
(0.101) 
−0.199** 
 (0.102) 
−0.203* 
 (0.112) 
−0.191* 
 (0.106) 
−0.145 
  (0.101) 
−0.183* 
 (0.102) 
−0.194* 
 (0.103) 
−0.198* 
 (0.104) 
−0.183* 
 (0.103) 
−0.221** 
 (0.105) 
HCERPC(-2) 
−0.342*** 
(0.067) 
−0.370*** 
(0.070) 
−0.322*** 
(0.074) 
−0.339*** 
 (0.072) 
−0.367*** 
(0.082) 
−0.341*** 
(0.068) 
−0.342*** 
(0.070) 
−0.341*** 
(0.071) 
−0.342*** 
(0.071) 
−0.332*** 
(0.072) 
GDPRPC(−1) 0.477*** 
    (0.161) 
0.485*** 
    (0.153) 
0.436*** 
    (0.160) 
0.516*** 
  (0.158) 
0.390** 
   (0.160) 
0.554*** 
   (0.153) 
0.499*** 
  (0.155) 
0.527*** 
    (0.153) 
0.489*** 
   (0.155) 
0.493*** 
   (0.154) 
GDPRPC(-2) 0.091 
    (0.182) 
0.121 
    (0.171) 
0.066 
     (0.177) 
0.132 
   (0.178) 
0.058 
   (0.183) 
0.229 
   (0.173) 
0.130 
   (0.173) 
0.146 
    (0.171) 
0.104 
   (0.173) 
0.110 
   (0.172) 
Number of obs. 100 100 100 100 100 100 100 100 100 100 
Wald test 
(p-level) 
0.006 0.005 0.020 0.004 0.041 0.001 0.004 0.002 0.005 0.004 
GDPRPC = real per-capita GDP growth rates (five-year averages), HCERPC = real per-capita health care expenditure growth rates (five-year averages) 
The Arellano-Bond one-step GMM estimator was applied. Standard errors are in parenthesis. *, ** and *** denote significance at the 10, 5 and 1 percent level, respectively. 
Estimates for constant terms not shown. 
